Biomimetic nanomedicines for precise atherosclerosis theranostics
Acta Pharmaceutica Sinica B
; (6): 4442-4460, 2023.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-1011192
Responsible library:
WPRO
ABSTRACT
Atherosclerosis (AS) is a leading cause of the life-threatening cardiovascular disease (CVD), creating an urgent need for efficient, biocompatible therapeutics for diagnosis and treatment. Biomimetic nanomedicines (bNMs) are moving closer to fulfilling this need, pushing back the frontier of nano-based drug delivery systems design. This review seeks to outline how these nanomedicines (NMs) might work to diagnose and treat atherosclerosis, to trace the trajectory of their development to date and in the coming years, and to provide a foundation for further discussion about atherosclerotic theranostics.
Full text:
Available
Database:
WPRIM (Western Pacific)
Language:
English
Journal:
Acta Pharmaceutica Sinica B
Year:
2023
Document type:
Article